Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Oncotarget|November 16, 2017
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migrationAsfar S Azmi, Yiwei Li, Irfana Muqbil, et al.
International Journal of Molecular Sciences|July 2, 2021
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer CellsMd Hafiz Uddin, Yiwei Li, Husain Yar Khan, et al.
Cancer Letters|October 4, 2016
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasoneIrfana Muqbil, Amro Aboukameel, Sivan Elloul, et al.
International Journal of Molecular Sciences|January 8, 2020
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy ResistanceHusain Yar Khan, James Ge, Misako Nagasaka, et al.
Scientific Reports|November 6, 2015
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionAsfar S Azmi, Irfana Muqbil, Jack Wu, et al.
Oncotarget|November 20, 2018
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionAmro Aboukameel, Irfana Muqbil, Erkan Baloglu, et al.
Oncotarget|October 8, 2016
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell deathTrinayan Kashyap, Christian Argueta, Amro Aboukameel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal AdenocarcinomaAsfar S Azmi, Husain Yar Khan, Irfana Muqbil, et al.
Cancers|December 5, 2019
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine TumorsGabriel Mpilla, Amro Aboukameel, Irfana Muqbil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I StudyErlene K Seymour, Husain Yar Khan, Yiwei Li, et al.
Pageof 4